A new study suggests that growing up in poverty accelerates biological development. For adolescent girls, this early onset of puberty provides a pathway linking financial hardship to increased anxiety ...
For the artificial intelligence expert, the greatest challenge is not which technology we use, but which human capacities we ...
The human brain has four distinct turning points where its structure changes, according to a study published in the journal Nature Communications, demonstrating that brain development is not as linear ...
AnaptysBio (NASDAQ:ANAB) is preparing to separate its business into two entities, with CEO Daniel Faga telling Barclays Senior Biotech Analyst Gena Wang that the company expects to create a new ...
Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an ...
Voyager Technologies, Inc. (NYSE:VOYG) Q4 2025 Earnings Call Transcript March 10, 2026 Operator: Welcome to the Voyager Technologies, Inc. Fourth Quarter and Full Year 2025 Financial Results ...
Although it was a relatively streamlined process, some degree of effort and curiosity was still required to effectively use Google. Now, with more and more people consulting AI chatbots for answers ...
More early-stage data show the drug, called salanersen, appeared to have positive effects on neurodegeneration and motor function in patients previously treated with Novartis' Zolgensma.
SONA 2026: Mahama delivered a performance on the state of his imagination — Mino... “And He taught you what you did not know. And ever great is the favour of Allah upon you.” ~Surah An-Nisa, 4:113 ...
Dupixent growth offsets Eylea declines; pipeline/Libtayo impact post-2026; monitor ROIC & SBC. Click for a REGN update.
Q4 2025 Earnings Call March 11, 2026 10:00 AM EDTCompany ParticipantsWarren Kanders - Executive Chairman & CEOBrad ...
STELLAR-2, a randomized, double-blind, sham-controlled study, will evaluate the effects of salanersen when initiated ~6 months after onasemnogene abeparvovec-xioi in infants with SMA who received ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results